Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Advanced Solid Tumor × spartalizumab × Clear all

Phase

Phase 1 2 Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Uterine Cervical Neoplasms 1 NSCLC 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 penpulimab 1 camrelizumab 1 atezolizumab 1 anlotinib 1 Inosine 1 Injections 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡